Gland Pharma said revenue from its core markets of the US, Europe, Canada and Australia grew by 3 per cent to Rs 747.5 crore in the second quarter, as against Rs 722.5 crore in the corresponding period last fiscal
Xtranet Technologies shares list at 7% premium over IPO price on NSE
Xtranet Technologies debuted at up to a 7% premium over its IPO price on Thursday, falling short of grey market expectations of an 11% gain.